NYSE:A (USA) Also trade in: Germany Mexico UK

Agilent Technologies Inc

$ 72.65 0.74 (1.03%)
Volume: 1,906,358 Avg Vol (1m): 2,874,355
Market Cap $: 22.96 Bil Enterprise Value $: 22.60 Bil
P/E (TTM): 20.86 P/B: 4.56
Earnings Power Value 23.84
Net Current Asset Value -0.26
Tangible Book 4.6
Projected FCF 33.09
Median P/S Value 47.82
Graham Number 18.97
Peter Lynch Value 70.57
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.20
Cash-To-Debt ranked lower than
62.07% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
A: 1.2
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.63, Med: 1.25, Max: 10000
Current: 1.2
0.63
10000
Equity-to-Asset 0.57
Equity-to-Asset ranked lower than
64.85% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
A: 0.57
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.31, Med: 0.51, Max: 0.71
Current: 0.57
0.31
0.71
Debt-to-Equity 0.35
Debt-to-Equity ranked lower than
60.37% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
A: 0.35
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.02, Med: 0.42, Max: 1.31
Current: 0.35
0.02
1.31
Debt-to-EBITDA 1.45
Debt-to-EBITDA ranked lower than
50.86% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
A: 1.45
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 1.45, Med: 2.14, Max: 11.3
Current: 1.45
1.45
11.3
Interest Coverage 13.24
Interest Coverage ranked lower than
66.87% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
A: 13.24
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.53, Med: 8.23, Max: 13.24
Current: 13.24
0.53
13.24
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.81
DISTRESS
GREY
SAFE
Beneish M-Score -2.26
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 25.5%
WACC 9.47%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 18.73
Operating Margin ranked higher than
88.43% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
A: 18.73
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 1.05, Med: 13.79, Max: 18.88
Current: 18.73
1.05
18.88
Net Margin % 22.26
Net Margin ranked higher than
65.15% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
A: 22.26
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -0.69, Med: 13.06, Max: 22.26
Current: 22.26
-0.69
22.26
ROE % 23.36
ROE ranked higher than
61.16% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
A: 23.36
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -1.22, Med: 12.51, Max: 26.86
Current: 23.36
-1.22
26.86
ROA % 12.80
ROA ranked higher than
62.60% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
A: 12.8
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -0.42, Med: 6.49, Max: 12.8
Current: 12.8
-0.42
12.8
ROC (Joel Greenblatt) % 77.59
ROC (Joel Greenblatt) ranked higher than
89.58% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
A: 77.59
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 7.79, Med: 44.69, Max: 83.45
Current: 77.59
7.79
83.45
3-Year Total Revenue Growth Rate 6.80
3-Year Revenue Growth Rate ranked lower than
51.10% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
A: 7.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -22.9, Med: 4.4, Max: 18.4
Current: 7.8
-22.9
18.4
3-Year Total EBITDA Growth Rate 15.50
3-Year EBITDA Growth Rate ranked higher than
62.36% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
A: 16.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -11.9, Max: 76.6
Current: 16.7
0
76.6
3-Year EPS w/o NRI Growth Rate -9.50
3-Year EPS w/o NRI Growth Rate ranked higher than
87.12% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
A: -9.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -34.1, Max: 135.6
Current: -9.5
0
135.6

» A's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:A

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 334516    SIC : 3825
Compare NAS:IDXX XSWX:LONN NYSE:MTD NYSE:IQV NYSE:LH TSE:6869 NYSE:WAT SHSE:603259 NYSE:DGX NAS:EXAS XTER:SRT NAS:DXCM XPAR:BIM NYSE:PKI NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR NAS:GH NAS:BRKR
Traded in other countries AG8.Germany 0HAV.UK
Address 5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (49% of sales), cross lab (which includes consumables and services at 34%), and diagnostics and genomics (17%). The United States and Europe account for 34% and 27% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California.

Ratios

Current vs industry vs history
PE Ratio (TTM) 20.86
PE Ratio ranked lower than
93.81% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
A: 20.86
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 5.2, Med: 20, Max: 126.81
Current: 20.86
5.2
126.81
Forward PE Ratio 23.47
Forward P/E ranked lower than
65.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
A: 23.47
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 20.86
PE without NRI ranked lower than
93.81% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
A: 20.86
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 5.2, Med: 23.59, Max: 126.81
Current: 20.86
5.2
126.81
Price-to-Owner-Earnings 29.07
Price-to-Owner-Earnings ranked higher than
61.84% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
A: 29.07
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 6.01, Med: 26.11, Max: 194.42
Current: 29.07
6.01
194.42
PB Ratio 4.56
PB Ratio ranked lower than
56.33% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
A: 4.56
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.22, Med: 2.89, Max: 5.34
Current: 4.56
1.22
5.34
PS Ratio 4.68
PS Ratio ranked lower than
58.70% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
A: 4.68
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.59, Med: 3.07, Max: 7.73
Current: 4.68
0.59
7.73
Price-to-Free-Cash-Flow 26.39
Price-to-Free-Cash-Flow ranked lower than
51.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
A: 26.39
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 5.4, Med: 20.41, Max: 68.05
Current: 26.39
5.4
68.05
Price-to-Operating-Cash-Flow 22.64
Price-to-Operating-Cash-Flow ranked lower than
56.70% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
A: 22.64
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.31, Med: 15.24, Max: 39.2
Current: 22.64
4.31
39.2
EV-to-EBIT 22.08
EV-to-EBIT ranked higher than
53.39% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
A: 22.08
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 4.9, Med: 22.2, Max: 249.8
Current: 22.08
4.9
249.8
EV-to-EBITDA 18.23
EV-to-EBITDA ranked higher than
52.27% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
A: 18.23
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 4, Med: 16.7, Max: 31.7
Current: 18.23
4
31.7
EV-to-Revenue 4.52
EV-to-Revenue ranked lower than
54.55% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
A: 4.52
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 3, Max: 7.6
Current: 4.52
0.7
7.6
PEG Ratio 1.67
PEG Ratio ranked lower than
100.00% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
A: 1.67
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.08, Med: 0.95, Max: 40
Current: 1.67
0.08
40
Shiller PE Ratio 34.38
Shiller PE Ratio ranked higher than
69.23% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
A: 34.38
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 9.84, Med: 24.11, Max: 46.42
Current: 34.38
9.84
46.42
Current Ratio 3.41
Current Ratio ranked higher than
60.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
A: 3.41
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.61, Med: 2.63, Max: 4.08
Current: 3.41
1.61
4.08
Quick Ratio 2.82
Quick Ratio ranked higher than
60.40% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
A: 2.82
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.04, Med: 2.17, Max: 3.44
Current: 2.82
1.04
3.44
Days Inventory 101.65
Days Inventory ranked lower than
56.86% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
A: 101.65
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 92.05, Med: 99.64, Max: 191.04
Current: 101.65
92.05
191.04
Days Sales Outstanding 59.56
Days Sales Outstanding ranked higher than
59.31% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
A: 59.56
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 47.45, Med: 55.63, Max: 84.27
Current: 59.56
47.45
84.27
Days Payable 50.42
Days Payable ranked lower than
62.57% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
A: 50.42
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 46.79, Med: 53.58, Max: 79.36
Current: 50.42
46.79
79.36

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 0.87
Trailing Dividend Yield ranked lower than
52.89% of 121 companies
in the Diagnostics & Research industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
A: 0.87
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.31, Med: 1.01, Max: 1.42
Current: 0.87
0.31
1.42
Dividend Payout Ratio 0.18
Dividend Payout Ratio ranked lower than
72.86% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
A: 0.18
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.09, Med: 0.33, Max: 0.77
Current: 0.18
0.09
0.77
3-Year Dividend Growth Rate (Per Share) 14.20
3-Year Dividend Growth Rate ranked lower than
100.00% of 36 companies
in the Diagnostics & Research industry.
Industry Max: 77.2, Med: 9.9, Min: -100
A: 14.2
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 14.2
Current: 14.2
0
14.2
Forward Dividend Yield % 0.91
Forward Dividend Yield ranked lower than
55.75% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
A: 0.91
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 1.07
Yield-on-Cost (5y) ranked lower than
53.52% of 142 companies
in the Diagnostics & Research industry.
Industry Max: 12, Med: 1.41, Min: 0.08
A: 1.07
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.38, Med: 1.24, Max: 1.74
Current: 1.07
0.38
1.74
3-Year Share Buyback Rate 1.40
3-Year Share Buyback Rate ranked higher than
95.00% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
A: 1.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -2.5, Med: 1.25, Max: 11.4
Current: 1.4
-2.5
11.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 15.79
Price-to-Tangible-Book ranked lower than
81.16% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
A: 15.79
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.1, Med: 4.07, Max: 18.88
Current: 15.79
1.1
18.88
Price-to-Projected-FCF 2.20
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
52.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
A: 2.2
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.6, Med: 1.32, Max: 3.73
Current: 2.2
0.6
3.73
Price-to-Median-PS-Value 1.52
Price-to-Median-PS-Value ranked lower than
90.16% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
A: 1.52
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.23, Med: 0.61, Max: 2.41
Current: 1.52
0.23
2.41
Price-to-Peter-Lynch-Fair-Value 1.03
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
A: 1.03
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.3, Med: 1.03, Max: 11.7
Current: 1.03
0.3
11.7
Price-to-Graham-Number 3.83
Price-to-Graham-Number ranked lower than
94.74% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
A: 3.83
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.84, Med: 2.32, Max: 9.2
Current: 3.83
0.84
9.2
Earnings Yield (Joel Greenblatt) % 4.51
Earnings Yield (Greenblatt) ranked higher than
79.25% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
A: 4.51
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 0.4, Med: 4.5, Max: 20.2
Current: 4.51
0.4
20.2
Forward Rate of Return (Yacktman) % 22.79
Forward Rate of Return ranked lower than
54.29% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
A: 22.79
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -10.2, Med: 18.6, Max: 36.5
Current: 22.79
-10.2
36.5

More Statistics

Revenue (TTM) (Mil) $ 5,019
EPS (TTM) $ 3.48
Beta 1.33
Volatility % 27.71
52-Week Range $ 60.42 - 82.27
Shares Outstanding (Mil) 315.99

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N